ramosetron has been researched along with Diarrhea in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Li, Y; Qi, Q; Zhang, Y; Zuo, X | 1 |
| Barbara, G; Barbaro, MR; De Ponti, F; Dothel, G; Raschi, E | 1 |
| Akiho, H; Fukudo, S; Ida, M; Matsueda, K; Nakashima, Y | 1 |
| Camilleri, M; Grover, M | 1 |
| Haruma, K; Hata, J; Imamura, H; Ishii, M; Kamada, T; Kusunoki, H; Manabe, N; Merchant, JL; Shiotani, A | 1 |
| Akiho, H; Fukudo, S; Haruma, K; Ida, M; Kinoshita, Y; Nakashima, Y; Nishida, A; Okumura, T | 1 |
| Akiho, H; Fukudo, S; Haruma, K; Hayashi, K; Ida, M; Kinoshita, Y; Nakashima, Y; Okumura, T | 1 |
| Akiho, H; Fukudo, S; Haruma, K; Hayase, H; Hongo, M; Ida, M; Matsueda, K; Nakashima, Y | 1 |
| Harasawa, S; Hiwatashi, N; Hongo, M; Matsueda, K; Sasaki, D | 1 |
| Akiho, H; Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Miyata, K; Nishida, A; Sasamata, M | 1 |
| Hosokawa, H; Murao, S | 1 |
| Bak, YT; Choi, MK; Choi, SC; Huh, KC; Kim, NY; Kwon, JK; Lee, JS; Lee, KJ; Lee, OY; Myung, SJ; Park, HJ; Rhee, PL; Sohn, CI | 1 |
| Clavé, P | 1 |
| Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M | 1 |
| Lee, JS; Lee, TH | 1 |
| Funatsu, T; Hirata, T; Keto, Y; Nakata, M; Sasamata, M | 1 |
| Ozaki, A; Sukamoto, T; Yoshidomi, M | 1 |
4 review(s) available for ramosetron and Diarrhea
| Article | Year |
|---|---|
Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
Topics: Abdominal Pain; Benzimidazoles; Constipation; Diarrhea; Humans; Irritable Bowel Syndrome; Serotonin 5-HT3 Receptor Antagonists | 2018 |
Advancements in drug development for diarrhea-predominant irritable bowel syndrome.
Topics: Animals; Benzimidazoles; Diarrhea; Drug and Narcotic Control; Drug Design; Gastrointestinal Agents; Humans; Imidazoles; Internationality; Irritable Bowel Syndrome; Phenylalanine | 2018 |
[Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
Topics: Animals; Benzimidazoles; Clinical Trials as Topic; Diarrhea; Dose-Response Relationship, Drug; Humans; Irritable Bowel Syndrome; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Stress, Psychological | 2009 |
Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
Topics: Abdominal Pain; Animals; Benzimidazoles; Defecation; Diarrhea; Dogs; Gastrointestinal Transit; Humans; Irritable Bowel Syndrome; Mice; Models, Animal; Rats; Serotonin Antagonists | 2007 |
6 trial(s) available for ramosetron and Diarrhea
| Article | Year |
|---|---|
Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Topics: Administration, Oral; Adult; Animals; Benzimidazoles; Chemical Phenomena; Diarrhea; Double-Blind Method; Feces; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Japan; Male; Middle Aged; Placebos; Rats; Treatment Outcome; Young Adult | 2014 |
Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
Topics: Adult; Benzimidazoles; Constipation; Diarrhea; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Japan; Middle Aged; Prospective Studies; Quality of Life; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; Sex Factors; Time Factors; Treatment Outcome; Young Adult | 2016 |
Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
Topics: Adult; Benzimidazoles; Diarrhea; Drug Administration Schedule; Female; Humans; Irritable Bowel Syndrome; Middle Aged; Serotonin Antagonists; Treatment Outcome | 2016 |
Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
Topics: Abdominal Pain; Adult; Benzimidazoles; Diarrhea; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Middle Aged; Serotonin Antagonists; Treatment Outcome | 2017 |
A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Benzimidazoles; Diarrhea; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Japan; Male; Middle Aged; Serotonin Antagonists; Treatment Outcome | 2008 |
Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
Topics: Adolescent; Adult; Benzimidazoles; Diarrhea; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Parasympatholytics; Phenethylamines; Republic of Korea; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Young Adult | 2011 |
7 other study(ies) available for ramosetron and Diarrhea
| Article | Year |
|---|---|
Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?
Topics: Animals; Benzimidazoles; Chemical Phenomena; Diarrhea; Feces; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Male | 2014 |
Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
Topics: Adult; Annexin A2; Benzimidazoles; Biomarkers, Pharmacological; Diarrhea; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; S100 Proteins; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Tryptophan Hydroxylase | 2015 |
Serotonin 5-HT3 receptor antagonist for treatment of severe diabetic diarrhea.
Topics: Adult; Antidiarrheals; Benzimidazoles; Diabetes Complications; Diarrhea; Enteric Nervous System; Humans; Male; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Severity of Illness Index; Treatment Outcome | 2010 |
Treatment of IBS-D with 5-HT3 receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets.
Topics: Benzimidazoles; Diarrhea; Humans; Irritable Bowel Syndrome; Male; Parasympatholytics; Phenethylamines; Serotonin 5-HT3 Receptor Antagonists | 2011 |
5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; Colonic Neoplasms; Cytokines; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; Gastrointestinal Agents; Gene Expression Regulation; Immunosuppressive Agents; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mucositis; Ondansetron; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2013 |
Ramosetron might be useful for treating diabetic diarrhea with a rapid small bowel transit time.
Topics: Antidiarrheals; Benzimidazoles; Diabetes Mellitus, Type 2; Diarrhea; Endoscopy, Gastrointestinal; Gastrointestinal Transit; Humans; Male; Middle Aged; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome | 2013 |
Effect of the 5-hydroxytryptamine3 (5-HT3)-receptor antagonist KB-R6933 on experimental diarrhea models.
Topics: Animals; Antidiarrheals; Benzimidazoles; Diarrhea; Loperamide; Male; Mice; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin Antagonists | 1999 |